TIGIT and cancer: In contrast, EpCAMlow, EpCAM− and full mesenchymal cancer cells downregulated the expression of PD-L1, CD112, and Gal9, and upregulated the expression of CD80 and CD155, ligands of CTLA-4 and TIGIT, respectively (Fig. 2a–e).